Lantheus (NASDAQ:LNTH) Issues Earnings Results

Lantheus (NASDAQ:LNTH) released its quarterly earnings data on Thursday. The medical equipment provider reported $1.27 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.27, Briefing.com reports. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The company had revenue of $384.01 million for the quarter, compared to the consensus estimate of $363.42 million. During the same period in the previous year, the business earned $1.70 earnings per share. The company’s quarterly revenue was up 1.4% on a year-over-year basis. Lantheus updated its FY 2025 guidance to 5.500-5.650 EPS.

Lantheus Price Performance

Shares of NASDAQ:LNTH traded down $2.62 during midday trading on Friday, reaching $51.07. The company’s stock had a trading volume of 1,757,334 shares, compared to its average volume of 1,261,428. The business’s fifty day simple moving average is $54.09 and its 200-day simple moving average is $68.72. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07. Lantheus has a fifty-two week low of $47.25 and a fifty-two week high of $111.29. The company has a market capitalization of $3.47 billion, a P/E ratio of 13.58 and a beta of 0.04.

Insider Transactions at Lantheus

In other news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the sale, the insider directly owned 3,477,227 shares in the company, valued at $195,246,296.05. This trade represents a 49.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 6,812,000 shares of company stock worth $382,427,380. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of LNTH. EverSource Wealth Advisors LLC raised its position in shares of Lantheus by 190.2% during the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock worth $87,000 after acquiring an additional 698 shares during the last quarter. First Trust Advisors LP boosted its holdings in Lantheus by 37.4% in the second quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider’s stock valued at $5,714,000 after acquiring an additional 19,008 shares during the last quarter. Baird Financial Group Inc. increased its position in Lantheus by 22.6% in the second quarter. Baird Financial Group Inc. now owns 2,715 shares of the medical equipment provider’s stock worth $222,000 after purchasing an additional 500 shares during the period. Daiwa Securities Group Inc. raised its holdings in Lantheus by 88.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,396 shares of the medical equipment provider’s stock worth $278,000 after purchasing an additional 1,591 shares during the last quarter. Finally, Osterweis Capital Management Inc. acquired a new position in Lantheus during the 2nd quarter valued at about $36,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. JMP Securities cut their target price on Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a research report on Thursday, August 7th. The Goldman Sachs Group set a $77.00 price objective on Lantheus and gave the company a “neutral” rating in a report on Wednesday, October 8th. William Blair restated a “market perform” rating on shares of Lantheus in a research note on Wednesday, July 16th. TD Cowen dropped their target price on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, September 15th. Finally, B. Riley cut their price target on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a report on Tuesday, September 16th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $74.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.